CellSeed Inc. (7776.T) has a MoatMap StockRank of 4/100 based on Quality (26/100), Value (34/100), and Momentum (19/100) factor scores. The current signal is STRONG SELL. CellSeed Inc. is a Japanese biotechnology company focused on regenerative medicine and cell sheet engineering. While the technology is scientifically interesting, the company is pre-revenue and highly speculative, failing the Terry Smith quality filter which demands high ROIC and established pricing power. It does not align with any of our active 18-month macro themes.
CellSeed Inc. is a biotechnology company specializing in regenerative medicine, utilizing its proprietary cell sheet engineering technology to develop regenerative tissues. The company commercializes temperature-responsive cell culture ware and is advancing clinical pipelines for corneal and cartilage regeneration. It operates as a pioneer in the regenerative medicine sector, aiming to replace traditional organ transplants with cell-sheet-based therapies.
| Price | $1.34 |
| Market Cap | $61M |
| Price/Book | 4.00 |
| Return on Equity | -71.7% |
| Return on Invested Capital | -78.1% |
| Debt/Equity | 15.50 |
| Gross Margin | 39.1% |
| Operating Margin | -569.7% |
| Revenue Growth | -71.6% |
| Free Cash Flow | $-23K |
CellSeed Inc. operates in the Biotechnology industry, part of the Healthcare sector (Japan).